[Prognostic value of bone and bone marrow lesions of primary myeloid metaplasia]. 1975

N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan

This study of the history of 117 cases of agnogenic myeloid metaplasia with myelofibrosis underlines the importance of anatomo-pathological and radiological parameters for prognosis. Histological staging of bone and bone marrow lesions at time of diagnosis enables one to confirm long survival of cases with hyperplasia (Group I) and more severe prognosis for advanced myelofibrosis (that is both groups II and III considered together) but does not enable to establish a significative difference between medium survival of cach group II and III considered separately. Those medium survivals estimated are the following: 82 months for group I; 60 months for both groups II and III. Thus, it is logical to consider together these two groups among which one can distinguish two anatomoclinical forms. One is characterized by bone marrow hyperplasia with reticulin myelofibrosis and is usually associated with large spleen and even in some cases with polycythemia but without radiologic bone lesions; the other is characterized by bone marrow of medium or hypoplasic constitution fibrosis, with or without osteosclerosis and with radiologic bone lesions of mode-rate or important extension (respectively 16.9 p. cent of cases) and is usually associated with pancytopenia.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D008533 Megakaryocytes Very large BONE MARROW CELLS which release mature BLOOD PLATELETS. Megakaryocyte
D010014 Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium. Osteolyses
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D001856 Bone Marrow Examination Removal of bone marrow and evaluation of its histologic picture. Examination, Bone Marrow,Bone Marrow Examinations,Examinations, Bone Marrow
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
January 1984, Sangre,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
October 2020, British journal of biomedical science,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
March 1997, Blood,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
September 1997, British journal of haematology,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
January 1989, Anticancer research,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
October 1978, American journal of clinical pathology,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
August 1961, Canadian Medical Association journal,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
May 1961, British medical journal,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
September 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology,
N Chelloul, and C Jacquillat, and J Brière, and M Laval-Jeantet, and W Vorhauer-Atlan
July 1984, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Copied contents to your clipboard!